文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

预测游离苯妥英浓度:白蛋白浓度与肾功能不全的影响

Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction.
PubMed 文献 · Pharmacotherapy · 2019-05-30

该回顾性研究纳入344例患者,评估多种公式预测游离苯妥英浓度的准确性。结果显示,白蛋白正常者即使合并轻中度肾功能不全,游离分数不变,无需测游离浓度;低白蛋白合并肾功能不全者各公式准确性均低,应直接测定游离苯妥英。

要点

  • 白蛋白正常且无蛋白结合置换剂时,轻中度肾功能不全无需测游离苯妥英。
  • 低白蛋白合并肾功能不全患者,预测公式准确性低,应直接测游离浓度。
  • Anderson法在白蛋白正常或仅低白蛋白患者中准确性最高。

核心结论

  • 白蛋白正常者合并轻中度肾功能不全时游离苯妥英分数不变,无需测游离浓度。
  • 低白蛋白合并肾功能不全者应直接测定游离苯妥英浓度。

研究设计与样本

  • 回顾性 chart review,纳入344例有游离及总苯妥英、白蛋白、血肌酐浓度的患者。

主要发现

  • 肾功能正常/白蛋白正常158例中Anderson法P20准确性86%。
  • 肾功能正常/低白蛋白73例中Anderson法准确性82%。
  • 轻度肾功能不全/白蛋白正常47例中Anderson法准确性92%。
  • 低白蛋白合并轻度或中度肾功能不全者,Winter-Tozer法准确性67%和50%,Anderson法56%和67%。
  • 低白蛋白合并重度肾功能不全14例中,无一系数P20准确性大于45%。

关键数值与推荐

  • P20指估计值在实测游离苯妥英浓度20%以内的比例。
  • Shiner-Tozer推导使用调整亲和系数C=0.15、0.20、0.25、0.30。

临床怎么用

  • 白蛋白正常且未用蛋白结合置换剂者,即使eGFR 30-90 ml/min/1.73 m2,可不测游离苯妥英。
  • 低白蛋白合并肾功能不全者,应直接测游离苯妥英浓度而非用公式预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Several methods are available to predict unbound (free) phenytoin concentrations in patients with hypoalbuminemia; however, predictive methods have not been evaluated in patients with concurrent hypoalbuminemia and kidney dysfunction or in patients with mild to moderate (estimated glomerular filtration rate [eGFR] 30-90 ml/min/1.73 m2 ) kidney dysfunction alone. Thus the objective was to evaluate the accuracy and precision of predictive methods to estimate free phenytoin concentrations in patients with varying albumin concentrations and/or kidney dysfunction. DESIGN: Retrospective chart review. SETTING: Large academic medical center. PATIENTS: A total of 344 patients with free and total phenytoin, albumin, and serum creatinine concentrations obtained between November 2012 and May 2017. MEASUREMENTS AND MAIN RESULTS: Free phenytoin concentrations were estimated in patients without kidney dysfunction using the Winter-Tozer, Anderson, Kane, and Cheng equations. For the analysis in patients with eGFR lower than 90 ml/min/1.73 m2 , free phenytoin concentrations were estimated using the Shiner-Tozer derivation with adjusted affinity coefficients (C = 0.15, 0.20, 0.25, and 0.30). For both analyses, accuracy of predictive methods was evaluated by P20, the proportion of estimations within 20% of the measured free phenytoin concentration. In 158 patients with normal kidney function/normal albumin concentrations, 73 with normal kidney function/hypoalbuminemia, or 47 with mild kidney dysfunction/normal albumin concentrations, the Anderson method had the highest accuracy (86%, 82%, and 92%, respectively) and highest precision compared with the other methods. In 47 patients with normal albumin concentrations and mild kidney dysfunction or 13 with moderate kidney dysfunction, the free fraction was unchanged, and total phenytoin concentrations accurately reflected free concentrations. In 17 patients with hypoalbuminemia and mild or 17 with moderate kidney dysfunction, the Winter-Tozer (67% and 50%, respectively) and the Anderson (56% and 67%, respectively) methods had the highest accuracy compared with other methods with significantly lower accuracy compared with patients with normal kidney function. In the 14 patients with severe kidney dysfunction and hypoalbuminemia, none of the coefficients had a P20 accuracy greater than 45%. CONCLUSION: In patients with normal albumin concentrations, with or without mild or moderate kidney dysfunction and not receiving a protein-binding displacer, the free fraction of phenytoin is unchanged, and it is not necessary to measure a free phenytoin concentration. Free phenytoin concentrations should be measured directly in patients with hypoalbuminemia and kidney dysfunction.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Montgomery MC, Chou JW, McPharlin TO, et al. Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction. Pharmacotherapy. 2019. PMID: 31067355. doi:10.1002/phar.2273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。